Retatrutide vs Semaglutide: Is Triple Agonism Really Better?
Semaglutide (Ozempic, Wegovy) is FDA-approved and widely prescribed. Retatrutide is the next-generation Eli Lilly candidate. Here's what the data actually say.
Semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for obesity) is the most-prescribed GLP-1 agonist in history. Retatrutide is Eli Lilly's investigational follow-up: a triple agonist hitting GLP-1, GIP, and glucagon receptors, reported to produce even larger weight reductions than semaglutide or tirzepatide in Phase II trials. As of early 2026, retatrutide is in Phase III and not yet approved.
Quick comparison
| Retatrutide (LY3437943) | Semaglutide | |
|---|---|---|
| Class | Triple agonist — GLP-1 + GIP + glucagon receptor | Single GLP-1 receptor agonist |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Regulatory status | Phase III (Triumph program). Not approved. | FDA-approved: Ozempic (2017 T2D), Wegovy (2021 obesity) |
| Weight loss (Phase II or labeled trials) | ~24% mean at 48 wk, 12 mg dose (👥 human, Phase II) | ~15% mean at 68 wk, 2.4 mg dose (👥 human, STEP-1) |
| Dosing | Weekly SC injection | Weekly SC injection (or daily oral Rybelsus) |
| Cardiometabolic data | Early (Phase II) liver fat reduction, glycemic improvement | Large — SELECT, SUSTAIN, STEP trials, CV benefit proven |
| Side effects | GI (nausea, vomiting, diarrhea) — dose-limiting | GI — same class effect |
What's actually different
Semaglutide activates just the GLP-1 receptor. GLP-1 slows gastric emptying, increases satiety, and enhances insulin secretion. Retatrutide activates three receptors simultaneously: GLP-1 (like semaglutide), GIP (like tirzepatide, the other Lilly drug), and glucagon (novel in this class). Glucagon receptor agonism sounds counter-intuitive for weight loss — glucagon raises blood glucose — but at the central level it promotes energy expenditure and at the hepatic level it drives lipolysis and hepatic fat reduction. The bet is that combining all three produces bigger weight loss with better metabolic outcomes than GLP-1 alone.
What the trials show
Phase II retatrutide data (Jastreboff et al., NEJM 2023) reported mean placebo-subtracted weight reductions of approximately 24% at the 12 mg weekly dose over 48 weeks in adults with obesity. Semaglutide's STEP-1 trial (Wilding et al., NEJM 2021) showed placebo-subtracted reductions of approximately 15% at the 2.4 mg weekly dose over 68 weeks. These are cross-trial comparisons — not head-to-head — so direct numerical ranking must be cautious. On numbers alone, retatrutide appears to produce the largest weight loss of any agent studied in humans to date, but Phase III data are still pending. Read the full Retatrutide review.
What semaglutide has that retatrutide doesn't
Approval. Ten years of post-marketing safety. Proven cardiovascular benefit (SELECT trial showed 20% reduction in MACE in overweight/obese adults without diabetes). A massive real-world evidence base. An established insurance pathway for obesity indications in multiple countries. Oral formulation (Rybelsus). Demonstrated benefit in kidney disease (FLOW trial) and potentially Alzheimer's (EVOKE trial ongoing). Retatrutide has none of this yet — it is a highly promising candidate in mid-clinical-development, not a proven therapy.
Side-effect profile
Both are GLP-1-class drugs and both have the same dose-limiting side effect: GI intolerance (nausea, vomiting, diarrhea) that typically improves with gradual dose titration. Thyroid C-cell tumor risk observed in rodents (not clearly translated to humans) is a class warning. Retatrutide has additional unique monitoring needs around glucagon activity — potential for transient tachycardia or modest blood-glucose elevation — which are being characterized in ongoing trials. Long-term retatrutide safety is still being established.
Which should you choose?
Semaglutide is approved and prescribable. Retatrutide is not yet approved. For any real clinical use today, semaglutide (or tirzepatide) is the available option. Retatrutide is worth following if you're interested in the obesity-pharmacotherapy pipeline, but "choosing" retatrutide today means obtaining it from grey-market research chemical sources — with all the purity, sterility, and dose-verification concerns that implies. Wait for Phase III and regulatory approval.
Sources
- Jastreboff A.M. et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med, 2023;389:514-526. PubMed 37366315
- Wilding J.P.H. et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med, 2021;384:989-1002. PubMed 33567185
- Lincoff A.M. et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." N Engl J Med, 2023;389:2221-2232. PubMed 37952131
Related comparisons
- Ipamorelin vs CJC-1295 — GH release
- BPC-157 vs TB-500 — healing peptides